Truth In Advertising - Logo

Class Action

Infants’ Tylenol

Class Action

Infants’ Tylenol

Share

June 2020: A federal court judge granted final approval of the settlement agreement.

December 2019: A federal judge preliminarily approved the settlement agreement. A final fairness hearing is scheduled for June 22, 2020. For more information, go to http://www.infantstylenolsettlement.com/.

September 2019: Plaintiffs moved for preliminary approval of a proposed settlement agreement. According to its terms, class members with proof of purchase may receive $2.15 for every bottle of Infants’ Tylenol purchased while class members without proof of purchase may receive $2.15 for up to seven bottles purchased (or a maximum award of $15.05). In addition, the company agreed to make changes to marketing materials for a period of two years, including modifying the image on the packaging for Infants’ Tylenol so that the child shown is at least two years old and disclosing on its websites and dosage charts for healthcare providers, as well as to consumers who complain or inquire, that the Infants’ and Children’s medicines contain the same concentration of acetaminophen.

November 2017: Plaintiffs filed an amended complaint similarly alleging that Infants’ Tylenol is marketed as “specially formulated for babies” when, according to the complaint, it is the same as the Children’s Tylenol.

October 2017: A class-action lawsuit was filed against Johnson & Johnson Consumer Inc. for allegedly deceptively representing that Children’s Tylenol and Infants’ Tylenol are different products in order to get consumers to pay more for Infants’ Tylenol when, according to plaintiffs, the medicines contain the same ingredients and the same dosages. (Elkies et al v. Johnson & Johnson Services, Inc. and Johnson & Johnson Consumer Inc., Case No. 17-cv-7320, C. D. Cal.)

For more of TINA.org’s coverage of the marketing of Tylenol products, click here.

Class-Action Tracker

Band-Aid Bandages

Class Action

Band-Aid Bandages

Allegations: Misleadingly marketing products as safe, healthy, made with the “best ingredients,” environmentally friendly, and committed to the health of consumers, communities and the planet

Sudafed PE

Class Action

Sudafed PE

Allegations: Falsely marketing that medicines treat congestion and other sinus issues

Tylenol Sinus

Class Action

Tylenol Sinus

Allegations: Falsely marketing that medicines treat congestion and other sinus issues

Aveeno Baby Products

Class Action

Aveeno Baby Products

Allegations: Misleadingly marketing products as specially made for babies when they contain the same formulation as the adult versions

Benecol Regular and Light Spreads

Class Action

Benecol Regular and Light Spreads

Allegations: Misleadingly labeling products as containing no trans fats and being safe for human consumption when the spreads contain partially hydrogenated oils, which are trans fats that increase the risk…

Zarbee’s Gripe Water

Class Action

Zarbee’s Gripe Water

Allegations: Misleadingly marketing that products “help[] ease occasional gas & stomach discomfort” associated with colic and hiccups in newborns when none of the ingredients have been shown to provide the…

OGX Shampoos and Conditioners

Class Action

OGX Shampoos and Conditioners

Allegations: Falsely representing that products smooth, nourish, soften, repair and revive hair without disclosing that ingredients in the products cause significant hair loss and irritate the scalp

OGX Shampoo and Conditioner

Class Action

OGX Shampoo and Conditioner

Allegations: Misleadingly marketing products will smooth, nourish, soften, repair and revive hair without disclosing that they contain an ingredient – DMDM hydantoin – that causes hair loss and scalp irritation

Lactaid Dietary Supplements

Class Action

Lactaid Dietary Supplements

Allegations: Misleadingly advertising that supplements prevent, treat, cure and mitigate lactose intolerance without FDA approval to make such claims

The Latest

Filters

Show More